# HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

> **NCT01701947** · — · NO_LONGER_AVAILABLE · sponsor: **Laboratoire français de Fractionnement et de Biotechnologies**

## Conditions studied

- Wound; Rupture, Surgery, Cesarean Section
- Postpartum Hemorrhage
- Surgery

## Interventions

- **BIOLOGICAL:** Hemoleven

## Key facts

- **NCT ID:** NCT01701947
- **Lead sponsor:** Laboratoire français de Fractionnement et de Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701947, "HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01701947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*